VDR and pancreatic neoplasm: Therapeutic strategies to target CAFs in pancreatic cancer include treatments that reduce the abundance of stroma in pancreatic cancer, such as nab‐paclitaxel, pegvorhyaluronidase alfa (PEGPH20), pirfenidone, SOM230 and CD40 agonists,53, 56, 57, 58, 59 and that reduce CAFs proliferation, including hedgehog pathway inhibitors, multi‐MMP inhibitors, TGF‐β inhibitor, retinoic acid53, 60, 61, 62 or vitamin D receptor activation to reprogram CAFs to a quiescent phenotype.63